Liraglutide - Drug Details

Liraglutide (Victoza, Saxenda)

Classification

GLP-1 receptor agonist

Mechanism of Action

Indications

Type 2 diabetes, weight management

Dosage and Administration

0.6 mg subcutaneously once daily, increased gradually to 1.2 mg

Forms

Injection

Side Effects

Nausea, vomiting, diarrhea, pancreatitis

Contraindications

Personal or family history of medullary thyroid carcinoma

Interactions

May increase the risk of hypoglycemia with sulfonylureas

Precautions

Monitor blood glucose regularly, avoid in patients with thyroid cancer

Pharmacokinetics

Half-life: 13 hours, excreted via urine

Pharmacodynamics

Enhances glucose-dependent insulin secretion

Storage Requirements

Store in refrigerator until opened, then at room temperature for up to 30 days

Patient Counselling

Counsel on potential gastrointestinal side effects and signs of pancreatitis

ClinicalMedHub - Modern Footer

ClinicalMedHub

Comprehensive medical resources, research tools, and professional networking for healthcare providers and patients worldwide.

Scroll down to see the modern footer design